While KIT is often mutated in gastrointestinal stromal tumors (GIST), which represents a targetable mutation with clinical benefit, it is rare in LMS, with mutations occurring in 1.8% of our cohort. This evidence concerns the gene KIT and gastrointestinal stromal tumor.